Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Wally R Smith, MD, Jane S. Hankins, MD MS, Miguel R Abboud, MD, Ze Cong, PhD, Jonathan Sorof, MD, Sarah Gray, PhD, Carolyn Hoppe, MD, Paul Telfer, DM, FRCP

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-137121

Published: 2020

Journal Articles

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Russell E. Ware, MD PhD, Clark Brown, MD PhD, Mariane de Montalembert, MD PhD, Margaret Tonda, PharmD, Barbara Tong, PhD, Carolyn Hoppe, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Miguel R. Abboud, MD

Blood (2019) 134 (Supplement_1): 1003.

https://doi.org/10.1182/blood-2019-130767

Published: 2019

Journal Articles

Chronic Kidney Disease Is Under-Screened in SCD and Mild Albuminuria Is Associated with a Drop in Hemoglobin: A Report from the Grndad Sickle Cell Registry

Elizabeth Williams, BA, Elizabeth Brown, Deepa Manwani, MD, Payal Desai, MD, Joshua J. Field, MD, Lynne D. Neumayr, Susan Padrino, MD, E. Leila Jerome Clay, MD MCTS, FAAP, Ze Cong, PhD, Irene Agodoa, MD, Carolyn Hoppe, MD, Sophie M. Lanzkron, MD, Jane A. Little, MD

Blood (2019) 134 (Supplement_1): 2284.

https://doi.org/10.1182/blood-2019-124933

Published: 2019

Journal Articles

Admixture In Sickle Cell Disease Defined By Genome Wide Ancestry Informative Markers Varies By Geographic Region In The United States

Zhengyuan Wang, Ph.D., Lena Diaw, Ph.D., Michael Dizon, Marci Barr, Meghan Quinn, Dominique Diggs, Darlene Allen, Cassie Seamon, RN, Anna Oguhebe, Deepika Darbari, MD, Yingze Zhang, PhD, Mark T. Gladwin, MD, Amy A. Hutchinson, Laurie Burdette, Carolyn Hoppe, MD, James G. Taylor, MD

Blood (2013) 122 (21): 995.

https://doi.org/10.1182/blood.V122.21.995.995

Published: 2013

Journal Articles

Microparticles As Biomarkers Of Osteonecrosis Of The Hip In Sickle Cell Disease

Anne M Marsh, MD, Raymond Schiffelers, PhD, Ginny Gildengorin, PhD, Frans A Kuypers, PhD, Carolyn Hoppe, MD

Blood (2013) 122 (21): 2226.

https://doi.org/10.1182/blood.V122.21.2226.2226

Published: 2013

Journal Articles

Evaluation of Moyamoya Disease in Sickle Cell Anemia Patients After Encephaloduroarteriosynangiosis

Janice Earl, FNP, Peter Sun, MD, Kenneth Martin, MD, Keith C. Quirolo, MD, Elliott Vichinsky, MD, Carolyn Hoppe, MD

Blood (2011) 118 (21): 1059.

https://doi.org/10.1182/blood.V118.21.1059.1059

Published: 2011

Journal Articles

Effect of Short-Term Simvastatin Treatment on Endothelial Adhesion Molecules in Sickle Cell Disease: A Pilot Study

Carolyn Hoppe, MD, Frans A Kuypers, PhD, Sandra K Larkin, Robert Hagar, MD, Elliott Vichinsky, MD, Lori A Styles, MD

Blood (2011) 118 (21): 1070.

https://doi.org/10.1182/blood.V118.21.1070.1070

Published: 2011

Journal Articles

Genetics of HbF and HbF Response to Hydroxyurea In Pediatric Sickle Cell Disease: A Multi-Site Pilot Analysis of Candidate SNP Variants

Nancy S. Green, MD, Katherine Ender, MD, MPH, Farzana Pashankar, MD, Catherine Driscoll, MD, Patricia Giardina, MD, Craig A. Mullen, MD, PhD, Lorraine Clark, PhD, Jennifer Crotty, PNP, Mara Burney, RN, MPH, Carolyn Hoppe, MD, Sandra Barral, PhD

Blood (2010) 116 (21): 2641.

https://doi.org/10.1182/blood.V116.21.2641.2641

Published: 2010

Journal Articles

Variation in the Small Guanosine Triphosphate (GTP)-Binding Protein, Secretion-Associated and RAS-Related (SAR1A) Gene and Response to Hydroxyurea Treatment in Sickle Cell Disease.

Chutima Kumkhaek, PhD, Jianqiong Zhu, MD, James G. Taylor, MD, Carolyn Hoppe, MD, Gregory J. Kato, MD, Griffin P. Rodgers, MD

Blood (2007) 110 (11): 3392.

https://doi.org/10.1182/blood.V110.11.3392.3392

Published: 2007

Journal Articles

Application of the Luminex Platform for Multiplexed Genotyping of Non-Deletional Alpha Thalassemia Mutations.

Sharon Aslanian, MS, Azimi Mahin, CLS, Carolyn Hoppe, MD

Blood (2005) 106 (11): 3841.

https://doi.org/10.1182/blood.V106.11.3841.3841

Published: 2005

Journal Articles

The TNF-a Gene Modifies Stroke Risk in Children with Sickle Cell Anemia: Results from the STOP Trial.

Carolyn Hoppe, MD, William Klitz, PhD, Katherine D’Harlingue, BS, Suzanne Cheng, PhD, Lori Steiner, MS, Robert Adams, MD, Lori Styles, MD

Blood (2005) 106 (11): 77.

https://doi.org/10.1182/blood.V106.11.77.77

Published: 2005

Journal Articles

An Effective Program to Resolve Ambiguous Results from State Newborn Hemoglobinopathy Screening.

Carolyn Hoppe, MD, Mahin Azimi, Sharon Aslanian, MS, Bertram Lubin, MD, Elliott Vichinsky, MD, Brad Therrell, PhD

Blood (2004) 104 (11): 3563.

https://doi.org/10.1182/blood.V104.11.3563.3563

Published: 2004

NARROW

Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Chronic Kidney Disease Is Under-Screened in SCD and Mild Albuminuria Is Associated with a Drop in Hemoglobin: A Report from the Grndad Sickle Cell Registry

Admixture In Sickle Cell Disease Defined By Genome Wide Ancestry Informative Markers Varies By Geographic Region In The United States

Microparticles As Biomarkers Of Osteonecrosis Of The Hip In Sickle Cell Disease

Evaluation of Moyamoya Disease in Sickle Cell Anemia Patients After Encephaloduroarteriosynangiosis

Effect of Short-Term Simvastatin Treatment on Endothelial Adhesion Molecules in Sickle Cell Disease: A Pilot Study

Genetics of HbF and HbF Response to Hydroxyurea In Pediatric Sickle Cell Disease: A Multi-Site Pilot Analysis of Candidate SNP Variants

Variation in the Small Guanosine Triphosphate (GTP)-Binding Protein, Secretion-Associated and RAS-Related (SAR1A) Gene and Response to Hydroxyurea Treatment in Sickle Cell Disease.

Application of the Luminex Platform for Multiplexed Genotyping of Non-Deletional Alpha Thalassemia Mutations.

The TNF-a Gene Modifies Stroke Risk in Children with Sickle Cell Anemia: Results from the STOP Trial.

An Effective Program to Resolve Ambiguous Results from State Newborn Hemoglobinopathy Screening.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only